PMID- 23272906
OWN - NLM
STAT- MEDLINE
DCOM- 20140213
LR  - 20211203
IS  - 1875-5992 (Electronic)
IS  - 1871-5206 (Linking)
VI  - 13
IP  - 7
DP  - 2013 Sep
TI  - Targeting mTOR: evaluating the therapeutic potential of resveratrol for cancer 
      treatment.
PG  - 1032-8
AB  - Resveratrol (3,4',5-trihydroxystilbene; RSV), a natural polyphenol found in a 
      variety of daily food including grapes and red wine, has long been suspected to 
      have multifaceted health beneficial properties, including anti-inflammation, 
      anti-oxidant, and anticancer activities. Over the past few years, numerous 
      studies have suggested that suppressing the activity of mammalian target of 
      rapamycin (mTOR), a critical regulator of cell metabolism, growth, and 
      proliferation, may provide a key mechanism underlying the anticarcinogenic 
      properties of resveratrol. It has been found that resveratrol targets multiple 
      components of the phosphatidylinositol 3- kinase(PI3K)/Akt and mTOR signaling 
      pathways, including PI3K, Akt, PTEN, and DEPTOR, suggesting that this natural 
      compound and its derivatives may offer a promising new cancer treatment. In the 
      current review, we discuss recent findings on the molecular mechanisms regulating 
      mTOR signaling and the therapeutic potential of resveratrol for cancer treatment 
      by targeting mTOR.
FAU - Wu, Yan
AU  - Wu Y
AD  - Second Xiangya Hospital, Metabolic Syndrome Research Center and Diabetes Center, 
      Institute of Aging and Geriatric Diseases, Key Laboratory of Diabetes Immunology, 
      Ministry of Education, Central South University, Hunan, China.
FAU - Liu, Feng
AU  - Liu F
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Anticancer Agents Med Chem
JT  - Anti-cancer agents in medicinal chemistry
JID - 101265649
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Antioxidants)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Stilbenes)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Antineoplastic Agents, Phytogenic/*pharmacology/therapeutic use
MH  - Antioxidants/pharmacology/therapeutic use
MH  - Humans
MH  - Molecular Targeted Therapy/methods
MH  - Neoplasms/*drug therapy/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Proto-Oncogene Proteins c-akt/antagonists & inhibitors/metabolism
MH  - Resveratrol
MH  - Signal Transduction/*drug effects
MH  - Stilbenes/*pharmacology/therapeutic use
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*metabolism
EDAT- 2013/01/01 06:00
MHDA- 2014/02/14 06:00
CRDT- 2013/01/01 06:00
PHST- 2012/01/29 00:00 [received]
PHST- 2012/12/05 00:00 [revised]
PHST- 2012/12/06 00:00 [accepted]
PHST- 2013/01/01 06:00 [entrez]
PHST- 2013/01/01 06:00 [pubmed]
PHST- 2014/02/14 06:00 [medline]
AID - CMCACA-EPUB-20121211-2 [pii]
AID - 10.2174/18715206113139990113 [doi]
PST - ppublish
SO  - Anticancer Agents Med Chem. 2013 Sep;13(7):1032-8. doi: 
      10.2174/18715206113139990113.